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Heart failure (HF) and chronic kidney disease (CKD) both carry significant risk for sudden cardiac death, hospital-
ization, and mortality; when combined, however, they markedly increase the risk of morbidity and mortality. De-
vice therapies such as implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT)
are treatments proven to have significant benefit on clinical outcomes in select patients with HF. However, the
majority of studies supporting the use of these devices have limited data on patients with CKD or end-stage re-
nal disease. In this review, we discuss the intersection of HF and CKD as it relates to progressive HF and the risk
of sudden death. Although these disorders are common and have a poor prognosis, the evidence available for
guiding treatment decisions for the use of ICD and CRT devices in these patients is lacking. Given this lack of
clear evidence, pragmatic clinical trials and comparative effectiveness studies are needed to help identify the
appropriate use of ICD and CRT devices in this high-risk population of patients with HF and CKD. (J Am Coll
Cardiol 2011;58:889–96) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.024C
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Heart failure (HF) and chronic kidney disease (CKD) are
each major health problems with an increasing prevalence.
More than 5 million adults currently have HF, and at 40
years of age, the lifetime risk for developing HF is approx-
imately 20% (1). Similarly, the prevalence of CKD, defined
by the presence of either reduced estimated glomerular
filtration rate (eGFR) or albuminuria, is approximately 16%,
with more than 8% classified as stage 3 or greater (eGFR
60 ml/min/1.73 m2) (2). Currently, there are more than
00,000 people living in the U.S. with end-stage renal
isease (ESRD), which represents a doubling in prevalence
ver each of the last 2 decades (2). The growth and severity
f HF and CKD will continue with the prevalence of HF
ncreasing and the progression of CKD to ESRD continu-
ng to steadily rise due to the aging population, increasing
ate of diabetes, and patient survival from initial cardiac
nsults such as acute coronary syndrome.
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2011, accepted May 24, 2011.Unfortunately, the prevalence of HF complicated by
KD is growing. Multiple studies have demonstrated that
early one-third of patients with HF have concomitant
tage 3 or greater CKD (3,4). CKD also carries a significant
isk for the development of HF. Patients with an eGFR
60 ml/min/1.73 m2 have a 3-fold higher risk for HF
compared with patients without CKD (5). Even worse,
more than 50% of patients starting renal replacement
therapy will develop symptomatic HF or left ventricular
(LV) dysfunction later in life (6).
Although a number of independent risk factors are
common to both HF and CKD, the combination of these
diseases amplifies the risk of poor outcomes (4,7). Patients
with HF and significant renal dysfunction have nearly 3
times the mortality risk when compared with patients
without significant kidney disease. Patients with ESRD
carry a 6- to 9-fold increase in death attributable to sudden
cardiac death (SCD) or malignant arrhythmias (Fig. 1) (2).
Although there are multiple pathways for LV dysfunction
and arrhythmogenesis in the general HF population, the
combination of HF and CKD leads to a perfect storm of
clinical risk for worsening HF and SCD. Much of the
decision making regarding device therapy in this subgroup
seems to be primarily based on expert opinion rather than
conclusive evidence (8). The goal of this review is to
summarize existing knowledge regarding the role of im-
plantable cardioverter-defibrillators (ICDs) and cardiac re-
synchronization therapy (CRT) in the prevalent, growing
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CKD and HF and to stimulate
future investigations.
Pathophysiology
Leading to Poor Outcomes
Multiple mechanisms lead pa-
tients with HF to develop kidney
disease. The decreased function
of the heart compromises stroke
volume, leading to adverse renal
hemodynamics. In addition, con-
gestion and increased central ve-
nous pressure limit renal perfu-
sion pressure and contribute to
worsening renal function (9).
One mechanism frequently pro-
posed to explain worsening renal
function in patients with HF is
verall reduced renal perfusion. However, HF patients with
reserved ejection fraction have similar eGFR when com-
ared with patients with reduced ejection fraction (10).
urthermore, this mechanism was assessed in the Evalua-
ion Study of Congestive Heart Failure and Pulmonary
rtery Catheterization Effectiveness trial, which concluded
hat poor forward flow did not account for the development
f worsening CKD in decompensated HF, and increased
ight atrial pressure, which may indicate renal congestion,
as the only hemodynamic parameter that was significantly
orrelated with impaired renal function (11). Others have
lso noted that venous congestion is among the most
Abbreviations
and Acronyms
CKD  chronic kidney
disease
CRT  cardiac
resynchronization therapy
eGFR  estimated
glomerular filtration rate
ESRD  end-stage renal
disease
HF  heart failure
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
LVRR  left ventricular
reverse remodeling
SCD  sudden cardiac
death
Figure 1 Mortality and Sudden Cardiac Death Across the Spec
Estimates of all-cause mortality (ACM) and sudden cardiac death (SCD) across the
and glomerular filtration rate (GFR) (background shaded curve) (2,15,40).mportant hemodynamic factors driving worsening renal
unction (12). Neurohormonal factors, anemia, medications,
nd natriuretic peptides are among other contributors to
orsening CKD in patients with HF (9).
The complications associated with CKD have the poten-
ial to negatively affect many of the stages of the classic
ardiovascular continuum leading to a more rapid progres-
ion to HF and an increased risk of SCD. Early in the renal
isease process, renovascular hypertension can lead to wors-
ning LV hypertrophy, atherosclerosis, and conduction
isturbances such as bundle branch blocks. Anemia of CKD
an worsen the progression of HF as a result of ineffective
lood volume and the adverse effects of inflammatory
ytokines on cardiomyocytes (13). Furthermore, the various
lectrolyte abnormalities observed in renal dysfunction,
ncluding hyperkalemia, uremia, and metabolic acidosis,
ontribute through multiple mechanisms to worsening car-
iovascular disease and increased risk of malignant arrhyth-
ias. CKD is frequently also associated with hypercalcemia,
nd renal function is inversely associated with coronary
rtery calcification, which significantly increases the risk for
dverse cardiovascular events (14). Many of these proar-
hythmic factors are even more arrhythmogenic in the
resence of scar tissue after myocardial infarction, which at
east partially explains why patients with CKD are at high
isk for SCD. A retrospective study evaluating patients with
KD undergoing cardiac catheterization found that every
0 ml/min/1.73 m2 decline in eGFR below 60 ml/min/
1.73 m2 was independently associated with a hazards ratio
HR) of 1.11 for SCD (15). Thus, there are multiple
athophysiological mechanisms to explain the heightened
of Chronic Kidney Disease
trum of chronic kidney disease (CKD)trum
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HF and CKD are independently associated with multiple
risk factors known to decrease survival (Fig. 2).
As patients develop ESRD, they accumulate even more
risk factors for SCD (Table 1). Prior studies have shown
that myocardial perfusion decreases during hemodialysis
and that SCDs have a temporal relation to hemodialysis
sessions (16). However, there are other factors beyond
dialysis itself associated with the increased risk of SCD. A
study evaluating the frequency of arrhythmias in 3 sub-
groups of patients (pre-dialysis renal failure, hemodialysis,
and renal transplant) without known cardiac disease failed
to demonstrate a statistically significant difference in the
frequency of arrhythmias and complex ectopic activity
between the 3 groups despite the correction of uremia by
successful transplant, indicating that myocardial dysfunction
was a more important determinant of complex arrhythmia
than dialysis or uremia in patients with CKD (17). Wors-
ening LV hypertrophy has been shown to be the strongest
predictor of SCD in patients undergoing hemodialysis (18).
The Evidence Base for ICD Therapy
Randomized clinical trials of ICD therapy in patients with
HF provide limited data regarding patients with CKD. In
most trials, those with renal dysfunction were either ex-
cluded or renal function was not reported (Table 2). The
most applicable data comes from a retrospective subgroup
analysis of patients enrolled in the Multicenter Automatic
Defibrillator Implantation Trial–II, in which for each
Figure 2
Risk Factors Common to Heart Failure and
Chronic Kidney Disease for Cardiovascular
Disease and Outcomes
Risk factors common to both heart failure and chronic kidney disease
contributing to arrhythmogenesis, disease progression, and death (6,41,42).10 ml/min/1.73 m2 reduction in eGFR, the risk of all-cause
mortality and SCD increased significantly by 16%
(p  0.005) and 17% (p  0.03), respectively (19). Among
those with an eGFR 35 ml/min/1.73 m2, ICD therapy
as associated with a significant survival benefit (overall risk
eduction for all-cause mortality 32% and for SCD 66%).
owever, no survival benefit was observed with ICD
herapy among patients with an eGFR 35 ml/min/1.73 m2
(HR: 1.09; p  0.84).
As stated, patients with CKD and HF have poor long-
term outcomes when compared with the general population.
Multiple studies have confirmed that this finding remains
present despite ICD implantation (20). A study by Tura-
khia et al. (21) evaluating 507 patients for the association of
pre-ICD implant renal function on all-cause mortality
demonstrated that for every 10 ml/min/1.73 m2 decrease in
eGFR, the adjusted hazard of death increased significantly
by 12%. A meta-analysis performed to evaluate the role of
ICD therapy in dialysis patients concluded that despite
having ICDs, patients receiving dialysis had a 2.7-fold
higher mortality compared with those not receiving dialysis.
However, comparing patients receiving dialysis and those
with CKD but not receiving dialysis, there was no signifi-
cant difference in mortality (relative risk: 1.62; 95% CI: 0.84
to 3.14) (22). Robin et al. (23) also concluded that survival
was significantly shorter for patients with ESRD compared
with non-ESRD patients (3.2 years vs. 7.4 years). Although
these studies did not compare patients without ICD ther-
apy, they confirm the risk of mortality with severe renal
dysfunction and the need to better elucidate the net-clinical
benefit of ICD therapy in these patients.
To the best of our knowledge, there are no randomized
controlled trials to adequately address the efficacy and safety
of ICD implantation in patients undergoing dialysis. A
Risk Factors for SCD inPatients With ESRD (16,18,23,43)Table 1 Risk Factors for SCD inPatients With ESRD (16,18,23,43)
Primary Difference in
ESRD Patients
Potential Cause for Increased
Risk of Arrhythmias and SCD
Cardiac structural
abnormalities
Reduced LVEF
LV hypertrophy
Increased prevalence of CAD
Narrowed coronary arteries
Dialysis procedure Myocardial ischemia/stunning
Atheroma formation/progression
Induced interstitial fibrosis and
vascular endothelial
dysfunction
Rapid electrolyte changes
Alteration in cardiac
autonomic function
Prolonged QT appearance of
late potentials
Sympathetic overactivity
Other Arterial hypertension
Increased rates of infection
CAD coronary artery disease; ESRD end-stage renal disease; LV left ventricular; LVEF left
ventricular ejection fraction; SCD  sudden cardiac death.recent retrospective cohort study by Hiremath et al. (24)
I
c
I
g
g
p
w
r
d
g
a
2
3
i
r
I
g
u
p
c
e
h
s
m
s
A
E
p
n
p
w
m
a

A
d
b
e
E
c
s
T
M
i
d
t
R
N HA  N
D
892 Cannizzaro et al. JACC Vol. 58, No. 9, 2011
Device Therapy in HF, CKD, and ESRD August 23, 2011:889–96comparing ESRD patients with LV dysfunction (defined as
ejection fraction 35%) who either did or did not undergo
CD placement concluded that the ICD group had signifi-
antly less all-cause mortality when compared with the no-
CD group (HR: 0.40), with a median survival in the ICD
roup of 8.0 years compared with 3.1 years in the no-ICD
roup.
A retrospective study by Herzog et al. (25) used a
ropensity model to compare ESRD patients who presented
ith ventricular fibrillation/cardiac arrest and did or did not
eceive ICD placement for secondary prevention within 30
ays. They found a significant survival benefit in the ICD
roup. They estimated that in the ICD group, 1-, 2-, 3-, 4-,
nd 5-year survival rates were 71%, 53%, 36%, 25%, and
2%, respectively; in the no-ICD group, they were 49%,
3%, 23%, 16%, and 12% (p  0.0001), respectively. ICD
mplantation was independently associated with a 42%
eduction in mortality risk. This study supports the use of
CDs in secondary prevention of SCD in patients under-
oing dialysis; however, uncertainty remains in defining the
se of ICD placement for primary prevention in these
atients.
ICD implantation also carries periprocedural risk, espe-
ially in patients with HF and CKD. Patients with an
GFR 60 ml/min/1.73 m2 were shown to have a 4.8-odd
igher risk for device infection when compared with control
ubjects (26). As technology improves, future devices may
itigate this risk; an example would be the use of entirely
ubcutaneous devices without intracardiac lead placement.
nother study to evaluate the risk profile of patients with
Major Trials Supporting ICD Use in Patients With Heart Failure andTable 2 Major Trials Supporting ICD Use in Patients With Hear
Trial (Ref. #) n Inclusion Criteria Interven
AVID (44) 1,016 Patients resuscitated from near-
fatal VF or had cardioversion
from sustained VT
ICD vs.
antiarrhyt
agents
CAT (45) 104 Recent onset of DCM (9 months)
and an EF 30%
ICD vs. contr
subjects
DEFINITE (46) 458 NIDCM, LVEF 36%, and PVCs or
NSVT
ICD vs. medi
treatment
MADIT-I (47) 196 NYHA I, II, or III with prior MI;
LVEF 35%; NSVT; and
inducible, nonsuppressible VT
on EP study
ICD vs. medi
treatment
MADIT-II (48) 1,232 Prior MI and LVEF 30% ICD vs. medi
treatment
MUSTT (49) 704 Prior MI; asymptomatic NSVT;
LVEF 40%; and inducible
sustained VT
ICD  antiar
agents
SCD-HeFT (50) 2,521 LVEF 35% and NYHA II or III ICD vs. amio
vs. placeb
AVID  Antiarrhythmics Versus Implantable Defibrillators; BUN  blood urea nitrogen; CAT 
Cardiomyopathy Treatment Evaluation; EF  ejection fraction; EP  electrophysiology; ESRD  end
interquartile range; LV left ventricular; MADITMulticenter Automatic Defibrillator Implantation
IDCM  nonischemic dilated cardiomyopathy; NSVT  nonsustained ventricular tachycardia; NY
eath in Heart Failure Trial; VF  ventricular fibrillation; VT  ventricular tachycardia.SRD after undergoing ICD placement compared with datients without ESRD found that ESRD patients had a
early 5 times higher risk of in-hospital mortality after ICD
lacement (1.9% vs. 0.4%; p 0.0001) (27). ESRD patients
ere also more likely than non-ESRD patients to have
ajor complications, including hematoma, vein thrombosis,
nd lead dysfunction requiring revision (29% vs. 5%; p 0.03).
Decision models have been developed to address the
concerns on the uncertain balance of risk and benefits for
ICD implantation in patients with CKD. For example,
Amin et al. (28) proposed a decision model analysis to help
guide the placement of ICDs for primary prevention in
patients with CKD. Their simulation favored ICD implan-
tation at age 80 years for eGFR 30 to 59 ml/min/1.73 m2,
age 75 years for eGFR 15 to 29 ml/min/1.73 m2, and age
65 years for eGFR 15 ml/min/1.73 m2 or hemodialysis.
lthough these results seem promising in guiding clinical
ecisions, the empirical data on which the assumptions were
ased are very limited. Furthermore, studies on cost-
ffectiveness in this population, especially those with
SRD, are even more limited, and prior calculations on
ost-effectiveness may be less applicable to this patient
ubpopulation (29).
he Evidence Base for CRT
ost of the major randomized controlled trials designed to
nvestigate the benefit of CRT in patients with HF were not
esigned (or powered) to assess the effects of renal dysfunc-
ion on outcomes (Table 3). In the CARE-HF (Cardiac
esynchronization Therapy in Heart Failure) trial, a pre-
orted Renal Characteristicsure and Reported Renal Characteristics
Baseline Renal Function
Renal Subgroup
Analysis
NA —
NA —
NA —
43 patients (22%) with BUN 25 mg/dl;
ESRD excluded
No
61 patients (5%) with BUN25mg/dl,
estimated GFR 68.823.9 ml/min/1.73m2;
ESRD excluded
Yes (19), no significant
difference in 2-yr all-
cause mortality for GFR
35ml/min/1.73m2
ic NA —
Mean creatinine 1.1 mg/dl
(IQR: 0.9–1.3 mg/dl)
No
iomyopathy Trial; DCM  dilated cardiomyopathy; DEFINITE  Defibrillators in Non-Ischemic
renal disease; GFR  glomerular filtration rate; ICD  implantable cardioverter-defibrillator; IQR 
myocardial infarction; MUSTTMulticenter Unsustained Tachycardia Trial; NA not available;
ew York Heart Association; PVC  premature ventricular complex; SCD-HeFT  Sudden CardiacRept Fail
tion
hmic
ol
cal
cal
cal
rhythm
darone
o
Card
-stage
Trial; MIefined analysis found that baseline eGFR was a significant
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tial benefit of the composite primary endpoint of all-cause
mortality or unplanned hospitalization for a major cardio-
vascular event was observed relative to renal function (/
median eGFR 60.3 ml/min/1.73 m2) (30). A retrospective
ubgroup analysis of the Multicenter InSync Randomized
linical Evaluation study found that in patients with an
GFR between 30 and 60 ml/min/1.73 m2, CRT improved
GFR when compared with the non-CRT group (6.4 2.4
l/min/1.73 m2 vs. 1.1  1.5 ml/min/1.73 m2; p 
0.008) (31). No difference was observed in patients with
eGFR 60 ml/min/1.73 m2, and there were too few
patients with eGFR 30 ml/min/1.73 m2 to draw any
meaningful conclusions. This subgroup analysis was the first
large placebo-controlled trial to report an improvement in
eGFR with the use of CRT in patients with impaired renal
function. Another retrospective subgroup analysis of the
COMPANION (Comparison of Medical Therapy, Pacing,
and Defibrillation in Heart Failure) trial concluded that in
CRT candidates, the risk for SCD was significantly increased
by renal dysfunction (HR: 1.69; 95% CI: 1.06 to 2.69; p 
0.03) (32,33). These findings are consistent with previously
identified increased risk of SCD in renal dysfunction.
Fung et al. (34) were among the first to identify a potential
Major Trials Supporting CRT Use in Patients With Heart Failure andTable 3 Major Trials Supporting CRT Use in Patients With Hea
Trial (Ref. #) n Inclusion Criteria Interve
CARE-HF (51) 813 NYHA III or IV; QRS 120
ms with standard
pharmacological
treatment
Medical treatme
COMPANION (33) 1,520 NYHA III or IV; ICM or NICM;
QRS 120 ms
Medical treatme
treatment  I
medical treat
ICD/CRT
MADIT-CRT (52) 1,820 NYHA I or II; ICM or NICM;
EF 30%; QRS 130 ms
ICD  CRT
MIRACLE (53) 453 NYHA III or IV; EF 35%;
QRS 130 ms
CRT vs. control s
MIRACLE ICD (54) 369 NYHA II or IV; EF 35%;
QRS 130 ms
All received ICD/
CRT inactivate
RAFT (55) 1,798 NYHA II or III; EF 30%;
QRS 120 ms or
paced QRS 200 ms
ICD  CRT
REVERSE (56) 610 NYHA I or II; EF 40%;
QRS 120 ms
All received CRT
(defibrillator
CRT inactive i
CARE-HF  Cardiac Resynchronization Therapy in Heart Failure; COMPANION  Comparison of Me
azard ratio; ICM  ischemic cardiomyopathy; MADIT-CRT  Multicenter Automatic Defibrillator
Clinical Evaluation study; NICM nonischemic cardiomyopathy; RAFT Resynchronization/Defibr
Left Ventricular Dysfunction trial; SCD  sudden cardiac death; other abbreviations as in Table 2.association between impaired renal function and worse clinicaloutcome among patients treated with CRT. They retrospec-
tively evaluated echocardiographic assessment and renal func-
tion tests before and 3 months after CRT in 85 consecutive
patients. Mean baseline eGFR was reported to be 56.9 19.7
ml/min/1.73 m2. Successful left ventricular reverse remodeling
(LVRR), which they defined as a reduction of LV end-systolic
volume of10%, was observed in 52% of patients after CRT.
They reported a small but significant improvement in eGFR in
those with LVRR when compared with those without at
3-month follow-up (2.5  7.0 ml/min/1.73 m2 vs. 13.1 
11.9 ml/min/1.73 m2; p  0.001). Of significance, they also
demonstrated a marked deterioration in eGFR in those who
did not have LVRR (61.9  17 ml/min/1.73 m2 vs. 48.8 
13.0 ml/min/1.73 m2; p  0.001). Change in eGFR after
CRT was significantly correlated with the changes in LV
end-systolic volumes, end-diastolic volumes, ejection fraction,
and mortality. Successful LVRR was the only independent
predictor of preservation of renal function after CRT. This
study indicated that changes in eGFR at 3 months after CRT
might clarify long-term prognosis in these patients. In addi-
tion, lack of significant LVRR after CRT may indicate a
high-risk group with potential for rapid decline in renal
function (34).
As for the role of CRT alone (without defibrillator
orted Renal Characteristicslure and Reported Renal Characteristics
Baseline Renal Function
Renal Subgroup
Analysis
RT Median estimated GFR 61ml/min/1.73m2
(IQR: 467–73ml/min/1.73m2)
Yes (30), no change in
the benefit of CRT for
the primary outcome
if GFR60 or
60ml/min/1.73m2
edical Not reported; 22% with “renal
dysfunction” (not specified)
Yes (32), HR: 1.69 for
SCD in patients with
renal dysfunction
24% with baseline BUN 26 mg/dl;
baseline creatinine 1.2 0.4 mg/dl;
ESRD excluded
No
s Not reported; excluded creatinine
3 mg/dl
Yes (31), CRT improved
GFR if baseline GFR
between 30 and 60
ml/min/1.73 m2;
mortality not reported
82
Not reported; excluded creatinine
3 mg/dl
No
GFR 30 ml/min/1.73 m2: 120 (7%);
GFR 30–59 ml/min/1.73 m2:
781 (43%);
GFR 60 ml/min/1.73 m2:
881 (49%)
No significant difference
between GFR 60 or
60 ml/min/1.73 m2;
no further analysis
CRT inactive: GFR 89.6 36.4 ml/min/
1.73 m2 CRT active: GFR 84.2 31.3
ml/min/1.73 m2
No significant difference
between GFR 82.7
ml/min/1.73 m2 or
82.7; no further
analysis
erapy, Pacing, and Defibrillation in Heart Failure; CRT  cardiac resynchronization therapy; HR 
ation Trial With Cardiac Resynchronization Therapy; MIRACLE  Multicenter InSync Randomized
for Ambulatory Heart Failure Trial; REVERSE Resynchronization Reverses Remodeling in SystolicReprt Fai
ntion
nt  C
nt vs. m
CD vs.
ment 
ubject
CRT;
d in 1
device
);
n 191
dical Th
Implantcapacity) in patients with ESRD, there is not enough
hroniza
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Device Therapy in HF, CKD, and ESRD August 23, 2011:889–96evidence to judge whether it is beneficial. As with the ICD
group, cost-effectiveness and safety are also issues in the
CRT group, including increased risk of infection and
procedural complications in patients with CKD. In a study
published in 2004 evaluating patients with HF, CRT was
associated with a median incremental cost of $107,800 per
quality-adjusted life-year gained (35). However, as ex-
pected, this benefit varied according to the presence of
comorbid illness, indicating that careful consideration
should be given to patients with shortened life expectancy,
such as those with CKD.
Adequate recommendations regarding the use of CRT in
patients with renal dysfunction cannot easily be made on the
basis of the literature available. Additional studies are
needed in this area to better evaluate the appropriate use and
effect of CRT on morbidity and mortality in such patients.
Future Directions
Potential future directions of research will likely require
multiple different study designs, including comparative ef-
fectiveness studies using existing observational data as well
as pragmatic randomized controlled trials. Leveraging rep-
resentative national databases with sufficiently large sample
sizes to examine device therapy and outcomes in patients
with HF and CKD will be useful in understanding the
scope of issues and potential areas of focus. Registries that
collect data and are linked to longitudinal outcomes may
allow further understanding of effectiveness and safety of
ICD/CRT placement accounting for baseline cardiac and
renal function as well as standard demographic and medical
background information. Furthermore, short-term proce-
dural complications, rehospitalization rates, and long-term
mortality rates may allow a better understanding of appro-
priate utilization of these interventions in the HF/CKD
population. Because of the limitations of using observational
data even with the use of methods to adjust for selection bias
and confounding, clinical trials remain an important area for
growth to improve the evidence base. As health care evolves,
allowing integration of electronic health records into every-
Key Questions Specific to ICD and/or CRT Placement in Patients WTable 4 Key Questions Specific to ICD and/or CRT Placement
1. What is the comparative effectiveness and safety in overall mortality across the
who do not receive device therapy?
2. Is there a difference in the rates of sudden cardiac death by CKD status overall?
including less invasive devices?
3. What pharmacotherapies are most effective for reducing the risk of arrhythmic
4. Do any current or emerging renal protective therapies influence the risk of arrhy
5. What is the optimal timing of ICD or CRT-D implantation in patients with CKD?
6. Do current patterns of practice vary with regards to device therapy in this popula
7. What is the cost-effectiveness of ICD and/or CRT in patients with CKD and symp
8. How does device therapy affect quality of life in this population?
9. Can risk stratification models or risk scores facilitate device implantation decisi
10. How can infectious risks and vascular access concerns be optimally addressed i
CKD  chronic kidney disease; CRT  cardiac resynchronization therapy; CRT-D  cardiac resyncday practice, use of observational data for comparativeeffectiveness studies as well as pragmatic clinical trials in the
“real-world” setting becomes more feasible. Although ques-
tions remain on whether the population of patients with
HF/CKD can be adequately studied, others are proving that
it is possible. For example, the ICD2 (Implantable Cardio-
verter Defibrillators in Dialysis Patients) trial, which has
been approved in the Netherlands, aims to determine
whether ICD therapy in dialysis patients age 55 to 80 years
results in a significant reduction in primary SCD rates when
compared with no ICD therapy (36). Regardless of the
method, additional evidence is needed to adequately guide
decision making.
Conclusions
The population of patients with both HF and CKD,
including ESRD, is already significant in size and is steadily
growing. These patients have an increased mortality risk
compared with other patients, making it even more essential
to identify the appropriate use of therapies that can improve
their overall survival, comorbidities, and quality of life. The
majority of the literature available regarding the use of
device therapy in this group of patients is based on retro-
spective data, which are subject to a myriad of biases,
particularly selection bias, which is not easily overcome even
with large datasets and multiple methods for adjustment.
Due to the paucity of evidence, neither the American
College of Cardiology/American Heart Association nor the
European Society of Cardiology guidelines for HF ade-
quately address this issue (37,38). Until more definitive
evidence is available, the management of such patients
should follow currently available American College of Car-
diology/American Heart Association guidelines for HF.
However, as with many therapies without clearly defined
guidelines, one must assess the risk/benefit ratio of device
therapy on an individual basis, particularly in ESRD pa-
tients with known HF, a subgroup that has been shown to
have a 2-year survival rate as low as 50% (39). Further
investigational studies are needed to help provide guidance
for the proper use of device therapy in this high-risk,
HF and CKDtients With HF and CKD
of CKD patients who undergo ICD and/or CRT placement compared with those
will the overall benefit improve with advancement in device therapy technology,
in patients with HF and CKD?
death in patients with HF?
nd why?
ic HF?
rticularly in terms of competing risks for mortality?
nts with CKD and HF who undergo device implantation?
tion therapy defibrillator; HF  heart failure; ICD  implantable cardioverter-defibrillator.ithin Pa
strata
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